The FDA switcheroo that's holding up Elite Pharmaceuticals Inc.'s Sequestox (oxycodone hydrochloride and naltrexone hydrochloride), the firm's abuse-deterrent opioid for pain "should not take that long" to resolve, CEO Nasrat Hakim said during a conference call intended to explain "why the FDA made that decision and how we're going to overcome it and get [the drug] approved."